Clavellina MM, Moreno CG

Language: Spanish
References: 39
Page: 47-51
PDF size: 216.76 Kb.

ABSTRACT

Although the mechanism of action remains obscure, dapsone and its metabolites have shown to be effective in two kinds of ailments: infections and chronic inflammatory diseases.
Dapsone is the drug of choice in dermatology for the treatment of certain inflammatory disorders and various neutrophilic, eosinophilic or autoimmune dermatoses.

REFERENCES

1. Fromm E, Wittmann J. “Derivate des p-nitrothiophenols”. Berichte Deutsch ChemGes 1908; 41: 2264-2273.

2. Doull JA. “Sulfone therapy of leprosy. Background, early history and present status”. Int J Lepr 1963; 31: 143-160.

3. Boyer H, Nitti F, Tréfouel J. “Note preliminaire sur l’action de la paradiacetyl- aminodiphenyl-sulfone (1399F) dans la blennorragie”. Bull Soc Fr Dermatol Syphiligr 1937; 44:1889.

4. Palazzoli M, Bovill D. “Action de la di (paracetyhiminophenyl) sulfone (1399F) dans les uretrites gonococciques aigues et chroniques”. Dermatol Syphiligr 1900-1910 (1937): 44.

5. Buttle GAH, Stephenson D, Smith S, et al. “The treatment of streptococcal infections in mice with diaminodiphenylsulfone”. Lancet 1937; 1: 1331-1334.

6. Fourneau E, Tréfouel J, Nitti F, et al. “Action anti-streptococcique derivés sulfurés organiques”. C R AcadSci 1937; 204: 1763-1766.

7. Faget GH, Pogge RC, Johansen FA, et al. “The promin treatment of leprosy”. Public Health Rep 1943; 58: 1729-1741.

8. Esteves J, Brandao FN. “Acerca da accao das sulfamidas e das sulfonas na doenca de Duhring. Trab Soc Portuguesa”. Dermatol Venereol 1950; 8: 209-217.

9. Sneddon IB, Wilkinson DS. “Subcorneal pustular dermatosis”. Br J Dermatol 1956; 68: 385-394.

10. Wozel G, editor. Dapson—Pharmakologie, Wirkmechanismus und klinischer Einsatz. Stuttgart (Alemania), Georg Thieme Verlag, 1996.

11. Ahmad RA, Rogers HJ. “Pharmacokinetics and protein-binding of dapsone and pyrimethamine”. Br J ClinPharmacol 1980; 10: 519-524.

12. Mc Evoy GK, editor. “AHFS drug information”. Bethesda (MD): American Society of Health-System Pharmacists; 2009; 605–609.

13. Zuidema J. “Clinical pharmacokinetics of dapsone”. Clin Pharmacokinet 1986; 11: 299-315.

14. Branski D, Kerem E, Gross-Kieselstein E, et al. “Bloody diarrhea—a possible complication of sulfasalazine transferred through human breast milk”. J Pediatr Gastroenterol Nutr 1986; 5: 316-317.

15. Sanders SW, Zone JJ, Foltz RL, et al. “Hemolyticanemia induced by dapsone transmitted through breast milk”. Ann Intern Med 1982; 96: 465-466.

16. Zhu YI, Stiller MJ. “Dapsone and sulfones in dermatology: overview and update”. J Am AcadDermatol 2001; 45: 420-434.

17. Wozel G, Barth J. “Current aspects of modes of action of dapsone”. Int J Dermatol 1988; 27: 547-552.

18. Niwa Y, Sakane T, Miyachi Y. “Dissociation of the inhibitory effect of dapsone on the generation of oxygen intermediate—in comparison with that of colchicine and various scavengers”. BiochemPharmacol 1984; 33: 2344-2360.

19. Niwa Y, Sakane T, Shingu M, et al. “Neutrophil-generated active oxygens in linear IgA bullous dermatosis”. Arch Dermatol 1985; 121: 73-78.

20. Miyachi Y, Niwa Y. “Effects of potassium iodide, colchicine and dapsone on the generation of polymorphonuclear leukocyte-derived oxygen intermediates”. Br J Dermatol 1982; 107: 209-214.

21. Hamada K, Hiyoshi T, Kobayashi S, et al. “Anticonvulsive effect of dapsone (4,40-diaminodiphenylsulfone) on amygdale-kindled seizures in rats and cats”. Epilepsy Res 1991; 10: 93-102.

22. Ishida S, Hamada K, Yagi K. “Comparing the anticonvulsive effects of dapsone on amygdale-kindled seizures and hippocampal-kindled seizures in rats”. Acta Neurol Scand 1992; 85: 132-135.

23. Altagracia M, Monroy Noyola A, Osorio Rico L, et al. “Dapsone attenuates kainic acid-induced seizures in rats”. Neurosci Lett 1994; 176: 52-54.

24. Díaz Ruiz A, Zavala C, et al. “Antioxidant, Antiinflammatory and Antiapoptotic Effects of Dapsone in a Model of Brain Ischemia/Reperfusion in Rats”. Journal of Neuroscience Research 2008; 86: 3410-3419.

25. Schumacher K. Humane “In-vivo-Untersuchungen zur antientzündlichen Wirksamkeit von Diaminodiphenylsulfon (Dapson)”. Departamento de Dermatología, Hospital Universitario Carl Gustav Carus, Dresden, Alemania 1996; tesis.

26. Pfeiffer CH, Wozel G. “Comments to ‘Dapsone and sulfones in dermatology: overview and update’”. J Am AcadDermatol 2003; 48: 308-309.

27. Gottfried W. “Innovative Use of Dapsone”. DermatolClin 2010; 28: 599-610.

28. Draelos ZD, Carter E, Maloney JM, et al. “Two randomized studies demonstrate the efficacy and safety of dapsone gel 5% for the treatment of acne vulgaris”. J Am Acad Dermatol 2007; 56: 439 e1-10.

29. Nestle FO, Kaplan DH, Barker J. “Mechanisms of disease: psoriasis”. N Engl J Med 2009; 361: 496-509.

30. Bundino S, Zina AM, Ubertalli S. “Infantile acropustulosis”. Dermatologica 1982; 165: 615-619.

31. Frayling IM, Addison GM, Chattergee K, et al. “Methaemoglobinaemia in children treated with prilocaine-lignocaine cream”. Br Med J 1990;301:153-154.

32. Grunwald MH, Amichai B. “Dapsone – the treatment of infectious and inflammatory diseases in dermatology”. Int J Antimicrob Agents 1996; 7: 187-192.

33. Coleman MD. “Dapsone toxicity: some current perspectives”. Gen Pharmacol 1995; 26: 1461-1467.

34. Rhodes LE, Tingle MD, Park BK, et al. “Cimetidine improves the therapeutic/ toxic ratio of dapsone in patients on chronic dapsone therapy”. Br J Dermatol 1995; 132: 257-262.

35. Stöckel S, Meurer M, Wozel G. “Dapsone-induced photodermatitis in a patient with linear IgA dermatosis”. Eur J Dermatol 2001; 11: 50-53.

36. Homeida M, Babikr A, Daneshmend TK. “Dapsone-induced optic atrophy and motor neuropathy”. Br Med J 1980; 281: 1180.

37. Kenner DJ, Holt K, Agnello R, et al. “Permanent retinal damage following massive dapsone overdose”. Br J Ophthalmol 1980; 64: 741-744.

38. Belmont A. “Dapsone-induced nephrotic syndrom”. JAMA 1978; 200: 262-263.

39. Hoffbrand BI. “Dapsone and renal papillary necrosis”. Br Med J 1978; 1: 78.